GlassScriptPhysician profile
Michelle E Cafaro
NPI 1619205655
$3,349.06
in general payments reported to CMS, 2019-2025
33 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $538 · 2023: $1,028 · 2024: $1,062 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $494.84 | 2022-2025 | |
| Lilly USA, LLC | $386.82 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $284.83 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $252.75 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Sumitomo Pharma America, INC. | $205.39 | 2023-2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $173.55 | 2023-2024 | Austedo Xr, Uzedy |
| Phathom Pharmaceuticals, INC. | $149.00 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $148.60 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $141.77 | 2022-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $134.22 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $100.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.97 | 2022-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $93.20 | 2022-2024 | Quviviq |
| Abbott Laboratories | $77.49 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Indivior INC. | $76.59 | 2024-2025 | Sublocade |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $75.88 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $74.50 | 2022-2025 | Airsupra, Farxiga |
| Collegium Pharmaceutical, INC. | $51.65 | 2023-2024 | Belbuca, Xtampza |
| Sunovion Pharmaceuticals INC. | $46.87 | 2022 | |
| Dexcom, INC. | $33.21 | 2022-2024 | Dexcom G6 Transmitter |
| Orexo US, INC. | $29.47 | 2022-2025 | Zubsolv |
| Hologic Sales and Service, LLC | $28.48 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $24.90 | 2025 | Neffy |
| Corium, LLC | $22.05 | 2023 | Azstarys |
| Scilex Pharmaceuticals INC. | $20.39 | 2025 | |
| Amgen INC. | $18.79 | 2025 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $17.97 | 2023 | Evkeeza |
| Janssen Pharmaceuticals, INC | $17.25 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.14 | 2022 | |
| Glaxosmithkline, LLC. | $14.59 | 2023 | Trelegy Ellipta |
| Pfizer INC. | $13.75 | 2023 | |
| Ibsa Pharma INC. | $13.36 | 2024 | Licart, Tirosint |
| Biohaven Pharmaceutical Holding Company LTD. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Cafaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.